FeesSafety
Pluang+

Regeneron to present key data on Ordspono and Lynozyfic blood cancer treatments at ASH 2026.

Market News
19 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Regeneron to present key data on Ordspono and Lynozyfic blood cancer treatments at ASH 2026.

Regeneron Pharmaceuticals announced it will share new and updated clinical data on its hematology drugs Ordspono (odronextamab) and Lynozyfic (linvoseltamab) at the American Society of Hematology (ASH) 2026 meeting. Highlights include pivotal trial results for Ordspono in relapsed/refractory marginal zone lymphoma and longer-term data for Lynozyfic in systemic light chain amyloidosis and multiple myeloma. These presentations underscore Regeneron's progress in developing innovative bispecific antibodies and siRNA therapies for blood cancers and disorders. The data could support regulatory approvals and expand treatment options for patients with limited therapies.

Regeneron Pharmaceuticals Inc (REGN) shares trade at USD 941.00 on Pluang as of Nov 19, 2026 19:15 WIB, down 0.48% in one day. The stock's market cap stands at $97.81 billion with a 52-week high of $973.36 and low of $600.66. Pluang order activity shows 90% selling and 10% buying, reflecting cautious investor sentiment amid new clinical data releases.

More News (REGN)

FDA approves Livsayis, first siRNA therapy for generalized myasthenia gravis with quarterly dosing

FDA approves Livsayis, first siRNA therapy for generalized myasthenia gravis with quarterly dosing

The FDA has approved Livsayis (cemdisiran), the first siRNA therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-AChR antibody-positive. Livsayis offers a novel treatment by targeting complement component C5, reducing dise...

Market News
Bullish
19 hours ago
CytomX hits $5M milestone with Regeneron on cancer drug collaboration using conditionally activated bispecifics

CytomX hits $5M milestone with Regeneron on cancer drug collaboration using conditionally activated bispecifics

CytomX Therapeutics announced it reached a $5 million preclinical milestone in its collaboration with Regeneron to develop conditionally activated bispecific antibodies for cancer treatment. This partnership combines CytomX's PROBODY® technology with...

Company Fundamentals
Bullish
1 day ago
Global biotech market hits $2.02T in 2026, set to triple by 2035 amid record deals and strong Q3 growth.

Global biotech market hits $2.02T in 2026, set to triple by 2035 amid record deals and strong Q3 growth.

The global biotechnology market reached a valuation of USD 2.02 trillion in 2026 and is projected to grow to USD 6.34 trillion by 2035, driven by a 13.61% CAGR. Leading companies like Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong thir...

Bullish
1 day ago
EU approves extended dosing and faster infusion options for cancer drug Libtayo

EU approves extended dosing and faster infusion options for cancer drug Libtayo

The European Commission has approved a new flexible dosing schedule for Regeneron's cancer drug Libtayo (cemiplimab), allowing a higher 700 mg dose every six weeks after an initial 12-week period of 350 mg every three weeks. Additionally, patients wh...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App